Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets
NEW YORK, March 24, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced it has entered into a strategic collaboration with EQRx, a company committed to developing and delivering innovative medicines to patients at radically lower prices.